Stockscreener 앱 받기
6.97
2.65%
-0.19
Arvinas Inc 주식(ARVN)의 최신 뉴스
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome - Zacks Investment Research
Reasons Why Investors Should Consider Betting on Arvinas Stock - Zacks Investment Research
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - Zacks Investment Research
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases - Zacks Investment Research
Arvinas, Inc. (NASDAQ:ARVN) Stock Has Average Price Target of $14.55 - MarketBeat
Arvinas presents phase 1 data for Parkinson’s drug ARV-102 - Investing.com
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease - GlobeNewswire Inc.
Arvinas Shares Novel Oculomotor and Biomarker Data from - GlobeNewswire
Arvinas to present ARV-102 Parkinson’s data at MDS congress - Investing.com
Arvinas to Present Novel Biomarker Data from the Phase 1 - GlobeNewswire
Parkinson’s drug trial data will be presented in a late-breaking oral session - Stock Titan
252,939 Shares in Arvinas, Inc. $ARVN Acquired by Bank of America Corp DE - MarketBeat
Arvinas (NASDAQ:ARVN) Shares Climb 6.3%What's Next? - MarketBeat
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Press Release: Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Arvinas enters immuno-oncology with HPK1 PROTAC degrader in Phase I/II trial - AllSci
Arvinas doses first patient in ARV-6723 cancer trial By Investing.com - Investing.com Nigeria
Arvinas doses first patient in ARV-6723 cancer trial - Investing.com
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate - GlobeNewswire Inc.
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical - GlobeNewswire
A cancer drug designed to remove a protein that limits immune activity enters human testing. - Stock Titan
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate - Yahoo Finance
Arvinas Q2 2026 Earnings Call Transcript - Benzinga
Arvinas (NASDAQ: ARVN) director plans stock sale under SEC resale rule - Stock Titan
Arvinas at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline takes center stage - investing.com
Arvinas at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline takes center stage - Investing.com Canada
Former Arvinas (NASDAQ: ARVN) officer plans new stock sale - Stock Titan
(ARVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod - Yahoo Finance
Arvinas at Wells Fargo conference: pipeline nears key data By Investing.com - Investing.com South Africa
Arvinas at Wells Fargo conference: pipeline nears key data By Investing.com - Investing.com Canada
Arvinas at Wells Fargo conference: pipeline nears key data By Investing.com - Investing.com India
Arvinas (ARVN) Stock Price, News & Analysis - Stock Titan
Former Arvinas (NASDAQ: ARVN) officer lines up new stock sale after recent trades - Stock Titan
Arvinas to Participate in Upcoming Investor Conferences - Yahoo Finance
Arvinas to Participate in Upcoming Investor Conferences - GlobeNewswire
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
ARVN Q2 2026 Earnings: EPS of $2.58 Blows Past Consensus; Stock Slips 0.65%Tax Rate Impact - vinanet.vn
The Technical Signals Behind (ARVN) That Institutions Follow - Stock Traders Daily
Arvinas Inc. (ARVN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Arvinas: Veppanu Approval Underlines Degrader Platform PromiseI'm Bullish (NASDAQ:ARVN) - Seeking Alpha
Arvinas (ARVN) Quarterly Results: EPS Lands Above Forecast for the Current Session; Trading Response: Shares Finish 4.54% Higher at the ClosePerformance Review - vinanet.vn
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Arvinas (ARVN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations at the Close; Price Reaction: Shares Move 0.22% Up in the Current UpdateEPS Growth Report - dars.gov.et
Arvinas (ARVN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations at the Close; Price Reaction: Shares Move 0.22% Up in the Current UpdateRevenue Miss Report - vinanet.vn
142,214 Shares in Arvinas, Inc. $ARVN Purchased by GSA Capital Partners LLP - MarketBeat
Arvinas Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
4.22%
자본화:
|
볼륨(24시간):